Since 1964 the author has seen and experienced the progress of nuclear medicine in Japan. The purpose of this review article is to trace the application of radiopharmaceuticals and instruments for the diagnosis of tumors and treatment of cancers in the past 55 years. The application of various radiopharmaceuticals for the detection of tumors and therapy of cancers are historically reviewed based on the author's personal clinical experience and research work. Nuclear medicine has been advanced by coordinated developments of instruments and radiopharmaceuticals like two wheels of a vehicle. The journey of nuclear medicine in the past was not necessarily a smooth one having met with periodic difficulties that changed its direction. The ways by which nuclear oncology has progressed by having overcome episodic problems are described. Future perspectives focusing on the recent trend of theranostics are described with the emphasis on efforts being made by the leadership of JSNM to contribute to the progress of nuclear medicine worldwide. The author believes that the multi-and trans-disciplinary collaboration of related specialists as well as other concerned parties will be necessary for the further progress of nuclear oncology in the future.
The author has seen and experienced the progress of nuclear medicine in Japan since 1964, when the Japanese Society of Nuclear Medicine (JSNM) was officially established. The 13th Asia and Oceania Congress of Nuclear Medicine and Biology held in May 2019 in Shanghai, China was a good opportunity to summarize the progress of nuclear oncology in Japan with the purpose to trace the track of applications of representative radiopharmaceuticals and instruments for diagnosis of tumors and treatment of cancers in the past 55 years.
The application of various radiopharmaceuticals for the detection of tumors and therapy of cancers are historically reviewed based on the author's personal clinical experience and research work in the past. Statistical trends of nuclear oncology in Japan are illustrated based on the nation-wide survey of nuclear medicine practice [1] conducted by the Japan Radioisotope Association every 5 years since 1982.
The author's perspective on the future development of nuclear oncology in Japan is described based on the review of the recent salient literature.
Personal experiences

How it began
In 1964, when the author started to receive training as an internist, he took charge of a 63-year-old female patient with late effects of thorotorast which had been intravenously injected 32 years previously. The final clinical diagnosis of the patient was made by detecting alpha-track in the liver biopsy specimen by micro-auto-radiography as well as by external gamma-spectrometry on the liver, which confirmed the presence of 232 Th in the liver [2] . The experience with this patient influenced the author to focus his professional career on Nuclear Medicine.
Thorotorast is a contrast medium, which was commercialized in 1929 and had been used in the 1930s and early 1940s. It contains 232 ThO 2 , an alpha-emitting radionuclide with a half-life of 14 billion years. Once injected as a colloid fluid, thorotorast persists in the reticuloendothelial system for life. Such long-lasting alpha irradiation caused liver cancer and other deleterious radiation effects 20-40 years after thorotorast injection. About 8000 cases with late effects of thorotorast have been reported in the world.
Scintillation scanner and 131 I-labelled compounds
In the 1960s scintillation-scanners and 131 I-labelled radiopharmaceuticals were used for imaging. A thyroid scintigraphy was taken 24 hours after oral administration of Na 131 I for detecting cancer as a cold nodule and functioning adenoma as a hot nodule ( Fig.1 ). 131 I-adosterol, an analogue of cholesterol, was used to detect adrenal adenomas in Cushing's syndrome and Conn syndrome with suppression of the contralateral normal adrenal gland (Fig.2 ). The signs/symptoms of these diseases disappeared after surgical resection of the tumors [3] .
Gamma cameras and 99m Tc-labeled compounds
It was fortunate that Anger-type gamma cameras with a large and thin crystal and 99m Tc with low energy (140 keV) and short half-life (6 h) gamma emitter became available at the same time in the 1960s. This so-called happy wedding revolutionized nuclear medicine practices, by making it possible to obtain dynamic images of rapid movement of a tracer.
This couple has been plying the major role in nuclear medicine in the half century since their marriage. The most frequently used nuclear medicine examination has been bone scintigraphy for detection of bone metastasis [4] , an example of which is shown in Fig.3 .
A solid state beta-detector and 32 P
As for the research in the early days, the author applied solid state beta detectors for oncology as well as cardiology [5] . A small silicon p-n junction diode was put into the tip of a catheter. The device was named catheter type semiconductor radiation detector or CASRAD, which was developed in TOSHIBA central research laboratory. It was inserted in the endoscopic device in place of a biopsy needle. The accumulation of 32 P injected 24 hours earlier was detected using this detector [6, 7] . The areas of infiltration of gastric and esophageal cancers were demonstrated as increased count rates as compared with normal tissues (Fig.4 ). The detection helps to identify appropriate tissues to be biopsied. 
C-breath tests using liquid scintillation counters
The author also used a simple breath collection apparatus to collect carbon dioxide in the breath after oral administration of 14 C compounds such as lactose [8] , glycine-cholate [9] , fatty acids and urea. Specific activities of 14 C dioxide were measured in a liquid scintillation counter ( Fig.5 ). Later a stable isotope 13 C was used together with a mass spectrometer [10] .
Breath analysis technique was applied for diagnosis of intestinal bacterial overgrowth by detecting the early peaks of 14 C exhaled as carbon dioxide after ingestion of 14 C-glycine cholate. 14 C-carbon dioxide exhaled in the breath is the final metabolite of 14 C-glycine which is released by bacterial de-conjugation of glycine-cholate. Likewise 14 C-urea was used to detect Helicobacter pylori infection in the stomach. 14 C-or 13 C-urea is metabolized by Helicobacter pylori with labeled carbon dioxide exhaled in the breath increasing. The 13 C urea breath test or UBT is now used as a routine clinical test that has been approved for reimbursement in the national health insurance system (NHIS).
125
I-anntibodies and well-type scintillation counters for in vitro radio-assays
Radioimmunoassay or RIA was invented in 1957 by S. Berson and R. Yallow, who received the Nobel Prize for this work in 2004. RIA and other in vitro radio assays were increasingly used in the 1970s as routine clinical tests utilizing 125 I for labeling and well-type counters to measure radioactivity.
Various tumor markers measured by RIA have been used to follow patients with cancers. Clinical applications of carcinoembryonic antigen or CEA in cancer patients are shown in Fig. 6 . Serial measurements of serum CEA revealed a rapid decline of CEA after resection of colon cancer (left), which indicates success of the operation and a good prognosis. In the other case of colon cancer (right), declined serum CEA levels after operation continuously increased again indicating recurrence of the cancer [11, 12] .
In vitro radio-assays boomed in the 1980s reaching a peak in 1987, but subsequently rapidly declined having been replaced by non-isotopic technology ( Fig.7) . 
Radio-immuno-detections (RID)
Labeled antibodies against tumor antigens were used to visualize cancer sites as the antibodies bind tumor antigens which were expressed on the surface of cancer cells. This new technology was called radio-immuno-detection or RID and attracted great interest in the 1980s. The author's groups conducted a clinical trial of IMACIS-1, which contains fragments (F (ab'2) ) of monoclonal antibodies against CEA and CA19-9 [13, 14] . 
SPECT and 201 TlCl
In the middle of the 1980s we started to use a single photon emission computed tomography or SPECT with 201 TlCl mainly for myocardial perfusion imaging [15] . The author's group in Gunma University used 201 Tl-SPECT for the detection of tumors [16] and malignant glioma of the brain [17] , which shows similar appearance as FDG PET. 201 Tl SPECT appears different from 99m Tc-DTPA image which demonstrates BBB disruption and 123 I-IMP image which reflects brain perfusion ( Fig.9 ).
PET/CT and FDG
In Japan the first PET center was started in 1979 at the National Institute of Radiological Sciences or NIRS in Chiba. The first home-made PET was called Positologica I and was used to obtain brain PETs using 13 NH 3 and 11 CO.
When a clinical PET center was started in 1984 in Gunma University Hospital a PET and a CT machine were installed side by side. A patient bed was moved electronically so that the PET and CT images could be taken in exactly the same position ( Fig. 10 ).
PET images of the brain were superimposed on the same slice level of CT images. An example of the combined image, which is now called a 'fusion image', demonstrates a tumor accumulating 11 C-methionine located in the sphenoidal wing (Fig.11) . This system was a proto-type PET/CT [18] , which was commercialized in 2000 as a system with PET and CT combined in tandem [19] . 
Trends of single photon and positron imaging
The trend of in vivo nuclear medicine imaging demonstrates an increase of PET with decreasing single photon imaging in the past 5 years as shown in Fig 12. In 2002 FDG PET examinations were approved as a procedure to be reimbursed by NHIS. In 2005 commercial delivery of FDG was started. These 2 epoch-making events accelerated the rapid increase [1] .
A unique application of PET and PET/CT in Japan is the use of FDG PET for health checkups. This application of PET has been controversial. A useful example is shown in Fig. 13 in which a 60-year-old non-symptomatic healthy male was diagnosed with lung cancer by health check-up using PET/CT. The cancer was removed by surgical operation and the patient survived.
Trends of radiopharmaceutical therapy, the way to theranostics
The trend of radiopharmaceutical therapy in the past 10 years in Japan is shown in Fig. 14. The statistics are based on the nation-wide survey of Nuclear Medicine practice which has been conducted every 5 years since 1982 by the Japan Radioisotope Association, or JRIA. The most frequently used radionuclide has been 131 I for the treatment of hyperthyroidism and thyroid cancers. Use of 89 Sr chloride for bone pain palliation has increased rapidly since 2007 reaching a peak in 2013. Unfortunately its supply was stopped recently. In 2017 223 Ra was approved for use under NHIS and was used for more than 4000 patients with castration resistant prostate cancer. Treatment of B-cell lymphoma with Zevalin, a combined use of 111 In and 90 Y-antibodies against CD20 is limited but constantly in use. The total number of patients treated by radiopharmaceutical therapy has increased to reach 14,000 per year in 2017.
In Japan the combined use of radiopharmaceuticals for diagnosis and therapy, which is called theranostics, is now evolving to routine clinical use.
Dr. Shoko Takano and her group at Yokohama City University demonstrated an example of theranostics in a 62-year-old female patient with neuroendocrine neoplasm (NEN) of pancreas origin and multiple liver metastases. Pretherapy CT demonstrated multiple low-density tumors in the liver, which accumulated 111 In-DOTATOC. The patient received peptide receptor radionuclide therapy (PPRT) using 90 Y-DOTATOC at Basel University Hospital. Post therapy CT showed a marked reduction in the size of the liver tumors. By November 2017 Dr. Takano's group sent 27 patients with NET diagnosed in Yokohama City University hospital to Basel University to be treated using 90 Y-DOTATEC with promising results [20] . 
Chronology of epochs-making events of nuclear oncology
The journey of nuclear medicine
The author has experienced nuclear medicine practice and research in Japan from its dawn to the present. The path of nuclear medicine has not been a smooth one. The coordinated development of instruments and radiopharmaceuticals has driven nuclear medicine like the two wheels of a vehicle. Similarly nuclear medicine has been successfully implemented by the tremendous cooperative efforts of physicians, technologists and other specialists in related fields.
There have been various epoch-making events during the half a century history of nuclear medicine, some representatives of which are described below.
CT impact
Soon after the discovery of X-rays Edison who invented various X-ray machines declared that he would show X-ray images of the human brain. He had to admit that his aim could not be achieved after repeated failures of his experiments. His dream came true 80 years later when Hounsfield invented computed axial tomography (CT) in the early 1970s. Although CT contributed remarkably to the accurate diagnosis of intracranial lesions such as tumors, infarctions and hemorrhages, it delivered an almost fatal blow to the clinical practice of nuclear medicine. Before the advent of CT, brain scintigraphy had been the only non-invasive imaging method to visualize and distinguish intracranial lesions such as tumors, hemorrhages and infarctions, and thus was the most clinically useful nuclear medicine procedure. Brain scintigraphy was rapidly replaced by CT. This so-called CT impact made the future prospects of nuclear medicine gloomy.
Nuclear cardiology and SPECT
The gloomy prospect was cleared and nuclear medicine was saved by the emergence of nuclear cardiology in the 1970s particularly by myocardial perfusion imaging (MPI) using 201 TlCl [15] . By the introduction of SPECT in the early 1980s nuclear cardiology became a major clinical procedure and focus of nuclear medicine research. Then the introduction of multi-detector CT (MDCT) in early 2000 and noninvasive coronary angiography led to new shadows falling over nuclear cardiology.
Nuclear oncology and FDG PET/CT
For decades 67 GaCitrate had been used for tumor imaging. In the first (1982) to fifth (2002) nation-wide survey of Nuclear Medicine Practices 67 Ga tumor scintigraphy ranked as the second or third most frequently performed procedure [21] . The image quality was not good and diagnostic efficacy was not very high. Therefore, 201 Tl was used for tumor images as a trial to increase the diagnostic efficacy of tumor imaging including glioblastomas. Clinical use of PET was promoted in the latter part of the 1980s. Approval of FDG PET for reimbursement under NHIS in 2002 and commercial delivery of FDG to hospitals in 2005 as well as commercially available PET/CT instruments facilitated the prevailing use of FDG PET for diagnosis and health check-up of cancers. Gallium scan and thallium scintigraphy for detection of tumors has been gradually replaced by FDG PET. The numbers of PET and PET/CT examinations have been increasing year by year. FDG PET and PET/CT account for 95 % of clinical PET examinations mostly for cancer patients.
Health checkups using FDG/PET were started in 1994 by Yamanakako Clinic, which reported a high detection rate of cancers reaching 2% in healthy volunteers. Health checkups using FDG PET and PET/CT became a boom in the early 2000s, which was however attenuated by the negative result reported by the National Cancer Hospital. Use of FDG PET and PET/CT for health checkup has been controversial due to relatively high radiation dose and high costs. The author believes it is useful for selected high risk groups of people, an example of which was shown in the text.
Immunology for nuclear medicine
Production of antibodies by immunizing animals such as rabbits, rats and mice had once been regarded as art rather than science, as the results cannot be predicted and depends on chance. The situation was completely changed in 1987 when Millstein invented the technology of controlled production of monoclonal antibodies and their fragments using genetic engineering.
Then radio-immuno-detection (RID) of cancers attracted interest as a new area of nuclear medicine. Later radioimmuno-therapy (RIT) became an important research objective as a part of radiopharmaceutical therapy. On the other hand, in vitro radio-assays typically using RIA has faded away in the past 20 years having been replaced by non-isotopic technology using typically fluorescent dyes as tracers.
Radiopharmaceutical therapy
H. N. Wagner, Jr. wrote "In the 1940s, the first reports of the use of radioactive iodine to treat diseases of the thyroid, and radioactive phosphorus to treat leukemia were greeted with great enthusiasm by the medical profession and the public. These classic findings were immediately recognized as forerunners of a whole series of similar uses of radioactive "magic bullets" " [22] . Even today radioiodine therapy of hyperthyroidism and thyroid cancers is increasingly used in Japan and elsewhere. Bone-seeking agents labeled with 89 Sr or 153 Sm have been used for relief of intractable bone pain. Alpha-emitting 223 Ra dichloride has been shown to prolong overall survival of patients with multiple bone metastases.
NENs which are characterized by their high level of somatostatin receptor (SSTR) expression can be confirmed by imaging with a SSTR binding radiopharmaceutical. The same radiopharmaceutical labeled with alfa or beta emitting radionuclide can be used for the treatment of metastatic NENs. The Food and Drug Administration (FDA) in the USA recently approved 177 Lu-DOTAA TAT E for PPRT of SSTR-positive gastroenteropancreatic NENs. The radiopharmaceutical is expected to be approved soon for clinical use in Japan also. The combination of diagnosis and therapy using a radiopharmaceutical is a typical example of theranostics.
Radiological protection
From the radiological protection point of view nuclear medicine is unique as a medical application of radiation, in which unsealed radioisotopes are administered to patients. The patients are exposed to radiation sources in the bodies. Nuclear medicine professionals need to be familiar with the recommendations of the International Commission on Radiological Protection (ICRP) and basic standards of International Atomic Energy Agency (IAEA) as well as domestic regulations on handling radioisotopes.
For decades, ICRP has developed dose coefficients and other information related to calculating doses to patients undergoing procedures using radiopharmaceuticals. Most recently these have been summarized in ICRP Publication 128 [23] .
In this publication, ICRP provides recommendations on radiological protection of patients, staff, and members of the public relating to radiopharmaceutical therapy. Nuclear medicine physicians who practice radiopharmaceutical therapy, doctors who prescribe it and other hospital staff who are involved need to be familiar with radiological protection considerations for patients and workers.
Having experienced the Fukushima Daiichi Nuclear Power Plant accident, the leadership of JSNM has placed emphasis on strengthening the system of radiological protection in hospitals. Diagnostic reference levels were established in 2016 by the collaboration of various societies and organizations involving physicians, technologists and nurses.
In the case of accidents and malicious acts, people with internal exposure to radioactive materials including plutonium and uranium must be hospitalized for radiation dose estimation and treatment. The most appropriate facilities to be used for those purposes are wards designed for radiopharmaceutical therapy. Special legal issues and technical considerations may be required to be prepared to use the wards for radiological emergencies with possible internal exposures. Surplus beds should be prepared to allow the facilities to be used in case of emergency. Staff should receive training with regular exercises to be prepared for this kind of nuclear or radiological medical emergency.
Future perspectives
It has long been recognized that the routine clinical use of new radiopharmaceuticals is limited in Japan. The approval process of new drugs is long and slow partially because of strict regulatory requirements. Relatively small market and insufficient reimbursement under NHIS cause radiopharmaceutical companies to adopt a prudent attitude for introduction for new drugs. In fact many patients with NENs have to receive 177 Lu-DOTATATE therapy abroad at their own expense, as the radiopharmaceutical has not been approved for routine use in Japan. Cooperation of physicians and chemists and pharmacists in research, which is essential for development of clinically useful new radiopharmaceuticals, should be further encouraged.
The present leadership of the Japanese Society of Nuclear Medicine (JSNM) has been making vigorous efforts to change the situation [24] in recent years. Taking promotion of theranostics for example, the strategy meeting for targeted radionuclide therapy (TRT) was established in 2012, which was reformed in 2016 to the National Conference for Nuclear Medicine Theranostics. In this conference nuclear medicine physicians, scientists, patients, persons supporting patients and industrial workers get together to discuss present and future development of theranostics. Japan Foundation of Medical Isotope Development (JAFMID) was launched in 2018 where multidisciplinary discussion is expected to be held for the domestic production of radioisotopes for medical use. Efforts have been made to increase communications between the JSNM leadership and government officials. Chances have been increasing for physicians in different specialties to get together and cooperate. These efforts have facilitated clinical trials, research [25] [26] [27] and the obtaining of official approval of new radiopharmaceuticals.
A powerful feudal load in the sixteenth century did not want his large territory to be separately governed by his three sons after his death. He gave each son an arrow and told them to break it. Each son could break one arrow easily. Then the father gave each son three arrows together, which nobody could break. This taught them that when three brothers unite their powers they can achieve more than the sum of individual power.
This legendary story demonstrates the importance of multi-and trans-disciplinary cooperation, which includes physicians, technologists, nurses, biologists, chemists, physicists, computer scientists and radiological protection specialists as well as government officials, industrial personnel and patients, for the future developments of nuclear medicine. This must continue to be the goal of all of us.
